LT3428274T - Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui - Google Patents
Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimuiInfo
- Publication number
- LT3428274T LT3428274T LTEP18182999.5T LT18182999T LT3428274T LT 3428274 T LT3428274 T LT 3428274T LT 18182999 T LT18182999 T LT 18182999T LT 3428274 T LT3428274 T LT 3428274T
- Authority
- LT
- Lithuania
- Prior art keywords
- interacting protein
- protein domains
- genome modification
- targeted genome
- enhance targeted
- Prior art date
Links
- 108010047956 Nucleosomes Proteins 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 210000001623 nucleosome Anatomy 0.000 title 1
- 108020001580 protein domains Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762531222P | 2017-07-11 | 2017-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3428274T true LT3428274T (lt) | 2021-11-25 |
Family
ID=62916578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP18182999.5T LT3428274T (lt) | 2017-07-11 | 2018-07-11 | Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui |
Country Status (17)
Country | Link |
---|---|
US (3) | US10604752B2 (lt) |
EP (2) | EP3988656A1 (lt) |
JP (2) | JP6994560B2 (lt) |
KR (3) | KR20240046316A (lt) |
CN (1) | CN111183226A (lt) |
AU (3) | AU2018299995B2 (lt) |
BR (1) | BR112019028261A2 (lt) |
CA (1) | CA3066790C (lt) |
DK (1) | DK3428274T3 (lt) |
ES (1) | ES2901629T3 (lt) |
GB (3) | GB2593814B (lt) |
IL (2) | IL271197B1 (lt) |
LT (1) | LT3428274T (lt) |
PL (1) | PL3428274T3 (lt) |
PT (1) | PT3428274T (lt) |
SG (1) | SG11201911864PA (lt) |
WO (1) | WO2019014230A1 (lt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111183226A (zh) | 2017-07-11 | 2020-05-19 | 西格马-奥尔德里奇有限责任公司 | 使用核小体相互作用蛋白结构域来增强靶向基因组修饰 |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
GB2587970B (en) | 2018-04-19 | 2023-02-08 | Univ California | Compositions and methods for gene editing |
WO2020036653A2 (en) * | 2018-04-25 | 2020-02-20 | The Regents Of The University Of California | Improved method for homology directed repair in cells |
CN111718418B (zh) * | 2019-03-19 | 2021-08-27 | 华东师范大学 | 一种增强基因编辑的融合蛋白及其应用 |
WO2020187272A1 (zh) * | 2019-03-19 | 2020-09-24 | 上海邦耀生物科技有限公司 | 一种用于基因治疗的融合蛋白及其应用 |
CN111718420B (zh) * | 2019-03-19 | 2021-09-14 | 华东师范大学 | 一种用于基因治疗的融合蛋白及其应用 |
EP3969574A1 (en) * | 2019-05-13 | 2022-03-23 | EMD Millipore Corporation | Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof |
WO2021224506A1 (en) * | 2020-05-08 | 2021-11-11 | Universitat Pompeu Fabra | Crispr-cas homology directed repair enhancer |
CN114507689B (zh) * | 2022-01-27 | 2024-01-16 | 山东大学 | 一种提高真核生物基因编辑效率的方法及其应用 |
CN115716880A (zh) * | 2022-12-07 | 2023-02-28 | 云舟生物科技(广州)股份有限公司 | 一种核定位荧光蛋白及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04005010A (es) | 2001-11-26 | 2005-04-08 | Advanced Cell Tech Inc | METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS. |
WO2004094613A2 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
US20130274129A1 (en) * | 2012-04-04 | 2013-10-17 | Geneart Ag | Tal-effector assembly platform, customized services, kits and assays |
CN105188767A (zh) * | 2012-07-25 | 2015-12-23 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
KR102210319B1 (ko) * | 2013-03-15 | 2021-02-01 | 더 제너럴 하스피탈 코포레이션 | 특정 게놈 좌위에 대한 유전적 및 후성적 조절 단백질의 rna-안내 표적화 |
US20140273230A1 (en) * | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
US10570418B2 (en) * | 2014-09-02 | 2020-02-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification |
WO2016049251A1 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
CA2963693A1 (en) | 2014-10-10 | 2016-04-14 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
US10190106B2 (en) * | 2014-12-22 | 2019-01-29 | Univesity Of Massachusetts | Cas9-DNA targeting unit chimeras |
CA2989827A1 (en) | 2015-06-17 | 2016-12-22 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
CN107922953B (zh) | 2015-08-20 | 2022-03-04 | 应用干细胞有限公司 | 提高基因编辑效率的核酸酶 |
CN111183226A (zh) | 2017-07-11 | 2020-05-19 | 西格马-奥尔德里奇有限责任公司 | 使用核小体相互作用蛋白结构域来增强靶向基因组修饰 |
-
2018
- 2018-07-10 CN CN201880046339.1A patent/CN111183226A/zh active Pending
- 2018-07-10 IL IL271197A patent/IL271197B1/en unknown
- 2018-07-10 KR KR1020247010966A patent/KR20240046316A/ko active Search and Examination
- 2018-07-10 WO PCT/US2018/041454 patent/WO2019014230A1/en active Application Filing
- 2018-07-10 JP JP2020501142A patent/JP6994560B2/ja active Active
- 2018-07-10 CA CA3066790A patent/CA3066790C/en active Active
- 2018-07-10 AU AU2018299995A patent/AU2018299995B2/en active Active
- 2018-07-10 IL IL309801A patent/IL309801A/en unknown
- 2018-07-10 BR BR112019028261-0A patent/BR112019028261A2/pt unknown
- 2018-07-10 SG SG11201911864PA patent/SG11201911864PA/en unknown
- 2018-07-10 KR KR1020207002645A patent/KR102523217B1/ko active IP Right Grant
- 2018-07-10 US US16/031,819 patent/US10604752B2/en active Active
- 2018-07-10 KR KR1020237012751A patent/KR102655021B1/ko active IP Right Grant
- 2018-07-11 ES ES18182999T patent/ES2901629T3/es active Active
- 2018-07-11 GB GB2103935.9A patent/GB2593814B/en active Active
- 2018-07-11 PL PL18182999T patent/PL3428274T3/pl unknown
- 2018-07-11 DK DK18182999.5T patent/DK3428274T3/da active
- 2018-07-11 LT LTEP18182999.5T patent/LT3428274T/lt unknown
- 2018-07-11 PT PT181829995T patent/PT3428274T/pt unknown
- 2018-07-11 EP EP21193940.0A patent/EP3988656A1/en active Pending
- 2018-07-11 EP EP18182999.5A patent/EP3428274B1/en active Active
- 2018-07-11 GB GB2114520.6A patent/GB2598847B/en active Active
- 2018-07-11 GB GB1811358.9A patent/GB2567917B/en active Active
-
2020
- 2020-02-18 US US16/793,272 patent/US20210024916A1/en active Pending
- 2020-02-18 US US16/793,253 patent/US20200208135A1/en active Pending
-
2021
- 2021-10-06 AU AU2021245148A patent/AU2021245148B2/en active Active
- 2021-12-13 JP JP2021201415A patent/JP7469285B2/ja active Active
-
2022
- 2022-02-09 AU AU2022200851A patent/AU2022200851B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2593814B (en) | Using nucleosome interacting protein domains to enhance targeted genome modification | |
IL295358A (en) | Use of programmable DNA-binding proteins to enhance targeted genome modification | |
HK1247636A1 (zh) | Rna指導的人類jc病毒和其他多瘤病毒的根除 | |
IL268894A (en) | Medical RNA | |
HK1249058A1 (zh) | 用於增强靶向蛋白質降解的化合物和方法 | |
SG11201707663SA (en) | Lyophilization of rna | |
SG11201701723XA (en) | Methods of treating liver disease | |
ZA201805634B (en) | Conjugate of therapeutic enzymes | |
SG11201507922TA (en) | Methods for enhancing muscle protein synthesis following concurrent training | |
IL259478B (en) | Conjugations of quaternary tubulin compounds | |
IL262419A (en) | A therapeutic composition containing enzyme-rich cannabis | |
MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
GB201711481D0 (en) | Protein purification | |
ZA201902689B (en) | Therapeutic protein | |
EP3265550C0 (en) | SYNERGIC REMOVAL OF PROTEIN SOIL USING A NEW COMBINATION OF CHELATORS | |
GB201411506D0 (en) | Modified latency associated protein construct | |
SG10201910999TA (en) | Native protein purification technology | |
GB201622116D0 (en) | Treatment of liver disease | |
GB201715784D0 (en) | Infant formula having decreased protein content | |
GB201704922D0 (en) | Methods of protein stapling | |
GB201712596D0 (en) | Improved photobioreactor | |
GB201710122D0 (en) | Purification of DNA | |
GB201616715D0 (en) | Therapeutic protein | |
EP3302067A4 (en) | Use of proteins to control molluscs | |
GB201521547D0 (en) | New therapeutic uses of enzyme inhibitors |